Xconomy’s EXOME Presents: New York Life Sciences 2021

Five years ago, in light of a major initiative by city, university, and industry leaders to spur growth in the local biotech cluster, Xconomy held an event called New York Life Sciences 2031. The idea was to look out 20 years to envision the changes the new efforts might bring. Few imagined things would have evolved so quickly. In the past five years, not only have big companies upped the ante in New York, the city has been teeming with an influx of startups, venture capital, and incubator spaces—not to mention key research initiatives such as the New York Genome Center and Tri-Institutional Therapeutics Discovery Institute.

The pace of change has been so rapid that we are inviting a new set of leaders to help us gaze just five years into the future. What will the life sciences landscape look like in 2021? Will the city have grown even more as a world leader in research, venture financing, and biotech entrepreneurial activity? Which fields will be the most vibrant? Join us at the Alexandria Center for Life Science for an interactive discussion of these and other key questions.

Speakers Include:

Joel S. Marcus has served as Chairman of the Board of Directors of Alexandria Real Estate Equities, Inc., since May 2007, Chief Executive Officer since March 1997, President since February 2009, and a director since the Company’s inception in 1994. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011.

Judith Dunn Ph.D., is a member of Roche’s pharma Research and Early Development Leadership Team; focused on the discovery and development of new medications that significantly improve the lives of patients. Judy leads several functions responsible for clinical execution across therapeutic areas including Oncology, Neuroscience, Inflammation, Ophthalmology and Infectious Diseases.

George Yancopoulos joined Regeneron in 1989 as its Scientific Founder. He received his M.D. and Ph.D. in Biochemistry and Molecular Biophysics from Columbia University and is a member of the National Academy of Sciences and the American Academy of Sciences. George is a principal inventor of Regeneron’s four FDA-approved drugs and foundational technologies for target and drug development. In 2014, he helped launch the Regeneron Genetics Center, a major new initiative in human genetic research.

Jeremy Levin D.Phil., MBBS, is the chief executive officer and chairman of the board at Ovid Therapeutics. He has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide.

Carlo Rizzuto, a Partner with Versant Ventures focuses on biotech investing and company building. Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.